Renaissance Technologies’s Kura Oncology KURA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.9M Sell
1,582,568
-247,998
-14% -$2.13M 0.02% 839
2025
Q4
$19M Buy
1,830,566
+965,256
+112% +$10.1M 0.03% 626
2025
Q3
$7.66M Sell
865,310
-191,700
-18% -$1.37M 0.01% 1227
2025
Q2
$6.1M Buy
1,057,010
+524,400
+98% +$3.21M 0.01% 1389
2025
Q1
$3.52M Sell
532,610
-65,200
-11% -$508K 0.01% 1647
2024
Q4
$5.21M Buy
597,810
+491,700
+463% +$7.08M 0.01% 1432
2024
Q3
$2.07M Sell
106,110
-15,090
-12% -$306K ﹤0.01% 1993
2024
Q2
$2.5M Sell
121,200
-119,000
-50% -$2.45M ﹤0.01% 1734
2024
Q1
$5.12M Sell
240,200
-37,900
-14% -$737K 0.01% 1390
2023
Q4
$4M Buy
278,100
+162,500
+141% +$1.6M 0.01% 1492
2023
Q3
$1.05M Sell
115,600
-72,500
-39% -$736K ﹤0.01% 2254
2023
Q2
$1.99M Buy
188,100
+171,500
+1,033% +$2.03M ﹤0.01% 2002
2023
Q1
$203K Buy
+16,600
New +$207K ﹤0.01% 3272
2022
Q4
Sell
-124,500
Closed -$1.7M 4267
2022
Q3
$1.7M Sell
124,500
-20,500
-14% -$316K ﹤0.01% 2123
2022
Q2
$2.66M Sell
145,000
-133,400
-48% -$1.92M ﹤0.01% 1986
2022
Q1
$4.48M Buy
278,400
+210,700
+311% +$3.04M 0.01% 1675
2021
Q4
$948K Sell
67,700
-106,400
-61% -$1.72M ﹤0.01% 2687
2021
Q3
$3.26M Sell
174,100
-128,100
-42% -$2.41M ﹤0.01% 1722
2021
Q2
$6.3M Buy
+302,200
New +$7.5M 0.01% 1489
2020
Q2
Sell
-85,271
Closed -$848K 3619
2020
Q1
$848K Buy
+85,271
New +$976K ﹤0.01% 2507
2018
Q1
Sell
-89,294
Closed -$1.37M 3474
2017
Q4
$1.37M Sell
89,294
-177,106
-66% -$2.61M ﹤0.01% 2533
2017
Q3
$3.98M Buy
266,400
+176,400
+196% +$1.66M ﹤0.01% 1906
2017
Q2
$837K Buy
90,000
+10,800
+14% +$98.3K ﹤0.01% 2627
2017
Q1
$697K Buy
79,200
+48,600
+159% +$356K ﹤0.01% 2666
2016
Q4
$181K Buy
30,600
+6,200
+25% +$33.2K ﹤0.01% 3021
2016
Q3
$153K Buy
24,400
+11,100
+83% +$56.2K ﹤0.01% 3115
2016
Q2
$36K Buy
+13,300
New +$41.4K ﹤0.01% 3256

Other funds holding KURA

Renaissance Technologies's KURA Position: Q1 2026 in Review

Renaissance Technologies reduced its Kura Oncology (KURA) stake by 14% in Q1 2026, selling an estimated $2.13M and leaving 1,582,568 shares worth $12.9M. The position accounts for 0.02% of the portfolio, ranked #839.

Renaissance Technologies first reported a position in KURA in Q2 2016 and has held it in 27 quarters since. The position peaked at $19M in Q4 2025. 220 funds tracked by Wall St. Rank hold KURA as of Q1 2026.

  • Renaissance Technologies held 1,582,568 shares of Kura Oncology worth $12.9M as of Q1 2026.
  • Renaissance Technologies sold 247,998 Kura Oncology shares in Q1 2026, an estimated $2.13M.
  • Kura Oncology made up 0.02% of Renaissance Technologies's portfolio in Q1 2026, its #839 holding.
  • Renaissance Technologies first reported a position in Kura Oncology in Q2 2016 and has held it in 27 quarters since.
  • Renaissance Technologies's Kura Oncology position peaked at $19M in Q4 2025.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.